NCT00116168已完成1 期
A Phase I, Open Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528, a Humanized Monoclonal Anti-Interleukin-9 Antibody, in Healthy Adult Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 3
- 主要终点
- Incidence of Changes From Baseline in the Day 28 Magnetic Resonance Imaging (MRI) of the Brain
研究概览
简要总结
A Phase I studyto evaluate the safety and tolerability of escalating subcutaneous (SC) doses of MEDI-528 in to healthy adult volunteers.
详细描述
The primary objective of this Phase I study is to evaluate the safety and tolerability of escalating single SC doses of MEDI-528 administered to healthy adult volunteers in four dose groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males and females age 19 up to, and including, 49 years of age at the time of the first dose of study drug
- •Weight less than 89 kg
- •Written informed consent obtained from the volunteer
- •Healthy by medical history and physical examination
- •Sexually active females, unless surgically sterile or at least two years post-menopausal or an FSH≥40 mIu/mL, must use an effective method of avoiding pregnancy (including oral, injectable, transdermal, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 3 months before the first dose of study drug, and must agree to continue using such precautions through the study period of 84 days. Cessation of birth control after this point should be discussed with a responsible physician. Sexually active males, unless surgically sterile, must likewise use an effective method of birth control (condom or abstinence) and must agree to continue using such precautions through Study Day 84 after their dose of study drug.
- •Use of common over-the-counter medications such as topical corticosteroids, decongestants, antihistamines, analgesics, and antacids is permitted unless, in the opinion of the investigator, it would interfere with either the volunteer's ability to complete the study or interpretation of the study results.
- •Ability to complete the follow-up period of 84 days
- •Willing to forego other forms of experimental treatment during the study period of 84 days
- •Willing to forego vigorous activity 1 - 2 days before dosing, and before each study visit.
排除标准
- •Acute illnesses or evidence of significant active infection, such as fever greater than or equal to 38.0 C (100.5°F) at the start of the study
- •Use of prescription medications, other than oral contraceptives, in the 28-day period before Study Day 0
- •Any blood donation or significant loss of blood within 6 months of time of entry into the study
- •History of immunodeficiency or receipt of immunosuppressive drugs
- •History of allergy or reaction to any component of the MEDI-528 formulation
- •History of substance abuse that, in the opinion of the investigator, may compromise the ability of the study subject to complete the study and follow-up period
- •Evidence of any systemic disease, neurologic abnormality, lymphadenopathy, or splenomegaly upon physical examination
- •Evidence of infection with hepatitis A, B, or C virus or HIV-1
- •Receipt of immunoglobulins or blood products within 60 days of entering the study
- •Receipt of any investigational drug therapy or standard vaccine therapy, other than vaccination for influenza, within 60 days of the first dose of study drug through Study Day 84 (use of licensed agents for indications not listed in the package insert is permitted)
- •Receipt of MEDI-528 in any previous clinical study
- •At Screening (must be within 21 days before study dose administration) any of the following: Hgb, total WBC, platelet count, Na, K, C1, CO2, AST, ALT, BUN, glucose, amylase, lipase, creatinine, or troponin out of the normal range; other abnormal laboratory values in the screening panel that, in the opinion of the principal investigator, are judged to be clinically significant
- •Clinically significant abnormality, as determined by the investigator, on 12-lead electrocardiogram at the time of initial screening
- •Clinically significant abnormalities noted on baseline brain MRI
- •Elective surgery planned during the study period through Study Day 84
- •Pregnancy (sexually active females must have a negative serum pregnancy test on the day of the first dose of study drug, before dosing)
- •Nursing mother
- •The presence of any condition or concern which, in the opinion of the investigator, may interfere with the conduct or interpretation of the study.
结局指标
主要结局
Incidence of Changes From Baseline in the Day 28 Magnetic Resonance Imaging (MRI) of the Brain
时间窗: Days 0 and 28
Number of participants with changes from baseline in the Day 28 MRI of the brain
Incidence of Serious Adverse Events
时间窗: Days 0 - 84
Number of participants experiencing serious adverse events
Incidence of Adverse Events
时间窗: Days 0 - 84
Number of participants experiencing adverse events (includes both adverse events and serious adverse events)
Incidence of Abnormal Troponin Levels
时间窗: Days 0, 1, 7, 14, and 28
Number of participants with troponin levels greater than upper limit of normal
Incidence of Clinically Significant Changes From Baseline in Neurologic Exam
时间窗: Days 0, 7, 14, 21, 28, 42, and 84
Number of participants with clinically significant changes from baseline in neurologic exam
次要结局
- Incidence of Anti-drug Antibodies (ADA) to MEDI-528(Days 0, 14, 28, 42, and 84)
- Time to Observed Maximum Serum Concentration (Tmax)(Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84)
- Observed Maximum Serum Concentration (Cmax)(Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84)
- Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)](Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84)
- Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)] of MEDI-528(Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84)
- Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)](Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84)
- Total Body Clearance (CL)(Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84)
- Half-life (T1/2)(Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84)
- Apparent Extravascular Terminal Phase Volume of Distribution (Vz/F)(Days 0, 1, 2, 3, 4, 5, 7, 10, 14, 21, 28, 42, and 84)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Phase I Study of CS1002 in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04338724CStone Pharmaceuticals6
已完成
1 期
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid TumorsAdvanced CancerMetastatic CancerNeoplasmsNeoplasm MetastasisNeoplastic ProcessesPathologic ProcessesNCT03510104Meryx, Inc.42
终止
1 期
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.CancerNCT01248858GlaxoSmithKline69
招募中
1 期
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver CancerAdvanced Liver CancerNCT05698459Binhui Biopharmaceutical Co., Ltd.12
终止
1 期
First in Human Trial of TAS266 in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT01529307Novartis Pharmaceuticals6